ADVA launches world’s first optical transport solution with post-quantum cryptography
8.7.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s first optical transport solution secured by post-quantum cryptography (PQC). The FSP 3000 ConnectGuard™ optical encryption solution now protects data against cyberattacks from quantum computers that could break today’s cryptographic algorithms. The quantum-safe security technology relies on a hybrid key exchange system, combining PQC algorithms with classical encryption methods. Built for crypto-agility, the solution is ready for software updates in the future, ensuring it delivers the most robust network protection now and for decades to come.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005050/en/
ADVA’s FSP 3000 ConnectGuard™ encryption solution now protects data against cyberattacks from quantum computers (Photo: Business Wire)
“Our market-first FSP 3000 quantum-safe ConnectGuard™ encryption technology answers the urgent threat posed by quantum computers and gives organizations a way to safeguard their networks before the danger materializes. Our customers’ data will be fully protected even from cybercriminals’ intent on harvesting information so that they can store it today and exploit it tomorrow,” said Christoph Glingener, CTO, ADVA. “We’re providing long-term security for data in motion. What’s more, our solution is ready to be upgraded later to comply with emerging specifications, including the NIST’s PQC standardization competition.”
As recommended by leading cybersecurity authorities, the PQC-protected ADVA FSP 3000 ConnectGuard™ encryption solution utilizes the traditional Diffie-Hellman protocol and combines it with a newly developed algorithm based on the quantum-safe McEliece cryptosystem. This enables it to produce encryption keys that even powerful quantum computers will be unable to crack. As well as delivering data integrity with quantum-safe Layer 1 AES-256 protection, the ADVA FSP 3000 ConnectGuard™ encryption solution ensures minimal impact on latency, throughput and performance. The technology is also easily deployable over long-haul and multi-operator links.
“Organizations everywhere have woken up to the security threat that quantum computing represents. With many experts anticipating powerful commercially available quantum computers in the next decade, it’s now widely understood that the danger is very real and the stakes are enormously high. That’s why we’ve invested so much time and energy into developing the world’s first transport solution ready for the challenges ahead,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “By integrating PQC security into our FSP 3000 ConnectGuard™ optical encryption solution, we’re empowering our customers to protect their networks today against tomorrow’s threats. Our solution is easily deployable and only requires end-point access. What’s more, it works over any distance and in any optical transport network.”
Watch this Tech Cam video for more information: https://youtu.be/4fs6zV5FnME.
Further details are also available in these slides: https://adva.li/pqc-slides.
A supporting solution brief can be downloaded here: https://adva.li/pqc-solution-brief.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005050/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release
LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
